bluebird bio, Inc. (NASDAQ:BLUE) Short Interest Update

bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totalling 2,410,000 shares, a decline of 6.6% from the December 15th total of 2,580,000 shares. Based on an average daily trading volume, of 405,100 shares, the days-to-cover ratio is currently 5.9 days. Currently, 25.0% of the company's shares are sold short.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Barclays raised their target price on bluebird bio from $2.00 to $40.00 and gave the company an "overweight" rating in a report on Tuesday, December 31st. StockNews.com began coverage on shares of bluebird bio in a research report on Friday, December 20th. They issued a "sell" rating on the stock. JPMorgan Chase & Co. lowered bluebird bio from a "neutral" rating to an "underweight" rating in a research report on Friday, November 15th. Bank of America cut shares of bluebird bio from a "buy" rating to a "neutral" rating and reduced their price target for the company from $60.00 to $10.00 in a research report on Friday, November 15th. Finally, Wells Fargo & Company lowered their target price on shares of bluebird bio from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Wednesday, September 25th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $49.14.

bluebird bio Price Performance

Shares of bluebird bio stock traded up $0.09 during trading on Friday, reaching $8.35. The company's stock had a trading volume of 109,879 shares, compared to its average volume of 426,810. The business has a 50 day moving average price of $8.12 and a 200-day moving average price of $12.23. The company has a market capitalization of $81.16 million, a P/E ratio of -0.22 and a beta of 0.68. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. bluebird bio has a 12-month low of $5.80 and a 12-month high of $38.40.

Institutional Investors Weigh In On bluebird bio

A number of large investors have recently bought and sold shares of BLUE. Bank of New York Mellon Corp lifted its position in shares of bluebird bio by 19.4% in the second quarter. Bank of New York Mellon Corp now owns 685,757 shares of the biotechnology company's stock valued at $675,000 after acquiring an additional 111,574 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of bluebird bio by 25.4% during the second quarter. Rhumbline Advisers now owns 292,436 shares of the biotechnology company's stock valued at $288,000 after buying an additional 59,219 shares during the period. AQR Capital Management LLC grew its stake in bluebird bio by 315.3% in the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company's stock worth $1,223,000 after acquiring an additional 1,013,144 shares during the period. SG Americas Securities LLC raised its holdings in bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 74,185 shares during the last quarter. Finally, FMR LLC lifted its stake in shares of bluebird bio by 8.1% during the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company's stock worth $1,289,000 after purchasing an additional 186,903 shares during the period. Institutional investors and hedge funds own 87.43% of the company's stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.